Cargando…

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelhorn, Heather L, Bacci, Elizabeth D, Poon, Jiat Ling, Boye, Kristina S, Suzuki, Shuichi, Babineaux, Steven M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966566/
https://www.ncbi.nlm.nih.gov/pubmed/27524889
http://dx.doi.org/10.2147/PPA.S109289
_version_ 1782445396758364160
author Gelhorn, Heather L
Bacci, Elizabeth D
Poon, Jiat Ling
Boye, Kristina S
Suzuki, Shuichi
Babineaux, Steven M
author_facet Gelhorn, Heather L
Bacci, Elizabeth D
Poon, Jiat Ling
Boye, Kristina S
Suzuki, Shuichi
Babineaux, Steven M
author_sort Gelhorn, Heather L
collection PubMed
description OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: “dosing frequency”, “hemoglobin A1c change”, “weight change”, “type of delivery system”, “frequency of nausea”, and “frequency of hypoglycemia”. Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. RESULTS: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation =10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation =5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). CONCLUSION: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients’ preferences that may be informative for patient–clinician treatment discussions.
format Online
Article
Text
id pubmed-4966566
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49665662016-08-12 Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan Gelhorn, Heather L Bacci, Elizabeth D Poon, Jiat Ling Boye, Kristina S Suzuki, Shuichi Babineaux, Steven M Patient Prefer Adherence Original Research OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: “dosing frequency”, “hemoglobin A1c change”, “weight change”, “type of delivery system”, “frequency of nausea”, and “frequency of hypoglycemia”. Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. RESULTS: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation =10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation =5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). CONCLUSION: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients’ preferences that may be informative for patient–clinician treatment discussions. Dove Medical Press 2016-07-25 /pmc/articles/PMC4966566/ /pubmed/27524889 http://dx.doi.org/10.2147/PPA.S109289 Text en © 2016 Gelhorn et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Gelhorn, Heather L
Bacci, Elizabeth D
Poon, Jiat Ling
Boye, Kristina S
Suzuki, Shuichi
Babineaux, Steven M
Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
title Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
title_full Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
title_fullStr Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
title_full_unstemmed Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
title_short Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
title_sort evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in japan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966566/
https://www.ncbi.nlm.nih.gov/pubmed/27524889
http://dx.doi.org/10.2147/PPA.S109289
work_keys_str_mv AT gelhornheatherl evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan
AT baccielizabethd evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan
AT poonjiatling evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan
AT boyekristinas evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan
AT suzukishuichi evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan
AT babineauxstevenm evaluatingpreferencesforprofilesofglucagonlikepeptide1receptoragonistsamonginjectionnaivetype2diabetespatientsinjapan